Cell子刊：徐沪济/孙凌云/杜冰团队使用通用型CAR-T细胞成功治疗系统性红斑狼疮

Core Viewpoint - The research highlights a significant breakthrough in the use of allogeneic CAR-T cell therapy for treating autoimmune diseases, specifically refractory systemic lupus erythematosus (SLE), demonstrating long-term remission and safety [2][3][4]. Group 1: Research Findings - The study published in Cell reported the successful use of allogeneic CD19-targeted CAR-T cells (TyU19) in treating refractory immune-mediated necrotizing myopathy and diffuse cutaneous systemic sclerosis, achieving long-term remission [1]. - In a subsequent study published in Med, the same CAR-T cell therapy was shown to effectively treat three patients with refractory SLE, leading to significant reductions in serum autoantibodies and achieving clinical remission as defined by the SRI-4 standard [3][6][7]. - The therapy demonstrated good tolerance, with no occurrences of graft-versus-host disease (GvHD), cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) reported during the study [9][10]. Group 2: Methodology and Safety - The clinical trial involved three patients with severe refractory SLE, where CAR-T cells were infused at a dose of 1 million cells per kilogram, and safety was assessed through the monitoring of potential adverse events [5][6]. - The CAR-T cells showed robust in vivo proliferation, peaking on day 14 post-infusion, and effectively eliminated B cells from the patients, leading to a significant decrease in B cell counts [6][9]. - The study utilized a low-intensity lymphocyte-depleting regimen, and even without pre-treatment lymphocyte clearance, TyU19 exhibited remarkable therapeutic efficacy, indicating a new potential pathway for treating autoimmune diseases [11].